European Pharmaceutical Review

MARCH 6, 2023

Investigators assessed whether administering a temperature-stable vaccine containing both ID93 and GLA-SE in a single vial would be as effective at inducing an immune response as a regimen in which non-thermostable ID93 and liquid GLA-SE are held in two vials and combined prior to injection. However, Sagawa et al.

Immunity 103

Immunity Immunization Vaccines Communication 103

European Pharmaceutical Review

OCTOBER 20, 2022

Recognising the potential of CAR T cells to act as highly targeted therapeutics, several biotechnology companies – including Sangamo Therapeutics – have established development pipelines of CAR T regulatory cells (Tregs) that aim to tackle immune?mediated What are Tregs and how are they applicable to immune-mediated disease?

Immunity 140

Immunity Immunization Drug Development 140

European Pharmaceutical Review

JUNE 13, 2023

Instead, the study tested for an immune response at levels that are thought to protect against the disease if infected with the virus. The post Chikungunya vaccine demonstrates 99 percent immune response appeared first on European Pharmaceutical Review. Results from the Phase III clinical trial was published in The Lancet.

Immunity 105

Immunity Immunization Vaccines 105

Express Pharma

JUNE 20, 2023

The vaccine efforts of the COVID-19 pandemic highlighted our knowledge about gaps in the immune system. Reductionist systems, such as genetically identical inbred mice, have long been the choice for immunology research, which focuses on studying the cells, tissues, and organs that make up the immune system.

Immunity 105

Immunity Immunization Vaccines Hospitals 105

World Pharma News

JANUARY 29, 2024

A new technology to increase visibility of cancer cells to the immune system using CRISPR has been developed, and could lead to a new way to treat cancer. Major histocompatibility complex (MHC) class I molecules are an immune complex present on the surface of all cells in humans.

Immunization 85

Immunization Immunity 85

pharmaphorum

NOVEMBER 4, 2021

While still preliminary, the experience with the two patients back up Talaris’ hope that giving a one-shot dose of FCR001 the day after an organ transplant could stimulate immune tolerance in the recipient, and avoid the side effects of current drug treatments such as infections, heart disease, and some forms of cancer.

Immunity 98

Immunity Immunization 98

Pharma Times

APRIL 17, 2023

Efti’s targeting activation of antigen-presenting cells delivers an adaptive immunity to fight cancer

Immunity 130

Immunity Immunization 130

ALiEM - Pharm Pearls

OCTOBER 11, 2024

A 76-year-old female presented with a lingering cough and an oral lesion to the left lower cheek. On the day of presentation, she developed a painful, intermittently bleeding “blood blister” to the left lower cheek that had increased in size, as well as new red spots on her arms and legs. Physical Exam Vitals : 98.3°F; Plt 6, WBC 10.3

Immunity 152

Immunity Immunization 152

Pharmafile

APRIL 1, 2025

Secarna Pharmaceuticals will present new preclinical data with its lead programme SECN-15 at the American Association for Cancer Research (AACR) taking place 25 to 30 April 2025 in Chicago, Illinois, US. Data will showcase SECN-15s potential to significantly improve the efficacy of immune checkpoint inhibitors (ICIs).

Immunity 59

Immunity Immunization 59

ALiEM - Pharm Pearls

MARCH 29, 2023

If LP is traumatic or pleocytosis is present, administer antibiotics and admit. Example: A 48-day-old infant presents with a fever of 100.6F, CRP of 22 mg/L, and otherwise normal procalcitonin, ANC, and UA. This requires a documented positive viral swab and not just a presentation consistent with a viral syndrome.

Hospitals 360

Hospitals Documentation Inpatient Immunity 360

ALiEM - Pharm Pearls

DECEMBER 18, 2023

A 19-year-old female with a past medical history of epilepsy presented to the emergency department for evaluation of rash and fever. Two days prior to presentation she began to experience fevers with a Tmax of 103°F. Diagnosis can be extremely challenging due to the variability in clinical presentation. Int J Mol Sci.

Immunity 177

Immunity Immunization 177

ALiEM - Pharm Pearls

OCTOBER 21, 2024

A 5-year-old generally healthy fully immunized boy presented to the ED with worsening left ear redness, swelling, and tenderness that his family noticed the day before presentation. His family had also recently noticed an abrasion over that ear.

Medical Schools 169

Medical Schools Immunity Immunization 169

Pharma Mirror

FEBRUARY 18, 2021

A novel approach for ensuring the virtually unlimited production of QS-21, the ‘Gold Standard’ adjuvant for improving vaccine efficacy, will be the subject of an upcoming presentation at the BIO CEO & Investor Digital Conference, starting February 16.

Immunity 52

Immunity Immunization Vaccines 52

Express Pharma

MAY 4, 2025

The available presentations are 45 mg/0.5 Yesintek is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases. Yesintek is available in all the same formulations currently provided by Stelara. mL PFS, 90 mg/mL PFS, 45 mg/0.5 mL vial, and 130 mg/26 mL vial.

Biosimilars 66

Biosimilars Immunization Immunity 66

pharmaphorum

SEPTEMBER 10, 2020

The spray is based on the SporeVax technology developed at Sporegen by Royal Holloway University Professor Simon Cutting and takes the form of heat killed spores of a bacterium – Bacillus subtilis – that stimulate a part of the innate immune system known as mucosal immunity.

Vaccines 133

Vaccines Adverse Reactions Immunity Immunization 133

pharmaphorum

AUGUST 2, 2022

In May, another amyloid targeting drug for Alzheimer’s disease – AC Immune and Roche’s crenezumab – missed the mark in another clinical trial and looked destined for the scrap heap like so many drugs in the class before it. The post AC Immune tries to resurrect crenezumab with new data delve appeared first on.

Immunity 52

Immunity Immunization 52

Pharmacy Joe

OCTOBER 18, 2023

In this episode, I’ll discuss why hypokalemia can result from digoxin immune fab fragment administration. With the administration of antidote therapy with digoxin immune fab fragments, the function of the sodium-potassium ATPase pump is restored.

Immunity 52

Immunity Immunization Hospitals Inpatient 52

Pharmacy Joe

OCTOBER 18, 2023

In this episode, I’ll discuss why hypokalemia can result from digoxin immune fab fragment administration. With the administration of antidote therapy with digoxin immune fab fragments, the function of the sodium-potassium ATPase pump is restored.

Immunity 52

Immunity Immunization Hospitals Inpatient 52

Express Pharma

SEPTEMBER 26, 2023

Their research, conducted in collaboration with scientists from Dayanand Medical College and Hospital in Punjab and the CSIR-Institute for Himalayan Bioresource Technology in Himachal Pradesh, presents a novel, faster, and more effective approach to producing vaccines for challenging infectious diseases.

Vaccines 111

Vaccines Immunity Immunization Hospitals 111

Express Pharma

OCTOBER 5, 2023

Data from these trials were most recently presented at the 2023 American Academy of Dermatology (AAD) Annual Meeting in March and previously presented at the 31st European Academy of Dermatology and Venereology Congress. The post US FDA accepts Sun Pharma’s NDA for Deuruxolitinib appeared first on Express Pharma.

Immunization 104

Immunization Immunity 104

pharmaphorum

JULY 18, 2022

CanSinoBIO’s inhalant has finished phase three trials in China and is presently undergoing trials in several countries. It then elicits an immune response against that spike protein. When you have mucosal immunity, the immunoglobulins called IgAs start neutralising the virus at the point of entry. The inhalant version.

Vaccines 138

Vaccines Health and Personal Care Stores Immunization Immunity 138

Pharmaceutical Technology

SEPTEMBER 14, 2022

Before TIL infusion, the patient undergoes lymphodepletion, which reduces the proportion of myeloid immune suppressive cells and creates space for the incoming lymphocytes. The high level of neoantigens in melanoma makes this the ideal setting for TIL therapy, with tumours often containing multiple clones of tumour-reactive immune cells.

Immunity 98

Immunity Immunization 98

Express Pharma

APRIL 17, 2023

Prometheus is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialisation of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases.

Immunity 98

Immunity Immunization Research Laboratories Labelling 98

Pharmafile

APRIL 3, 2023

aVaxziPen, a biotech company focusing on the development of a novel needle-free vaccine delivery platform, has announced that it will present data at the World Vaccine Congress (WVC) in Washington, US. read more

Vaccines 72

Vaccines Immunity Immunization 72

European Pharmaceutical Review

SEPTEMBER 20, 2023

Results of a Phase I/II study has revealed that a booster dose of a novel, self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine induces a robust, broadly cross-reactive, and durable immune response in adults. All three vaccines induced robust neutralising immune response against the D614G variant at Day 29.

Vaccines 98

Vaccines Immunity Immunization 98

Pharmafile

APRIL 18, 2023

read more

Immunity 40

Immunity Immunization Vaccines 40

Pharmaceutical Technology

SEPTEMBER 5, 2022

The needle-free vaccine can also elicit complete immune protection against the SARS-CoV-2 virus after just a single inhalation. According to studies, Convidecia Air could prompt robust cellular, humoral and mucosal immunity to attain triple protection as well as control the virus spread and the infection.

Vaccines 105

Vaccines Immunity Immunization 105

Express Pharma

AUGUST 27, 2024

This method is time-efficient and expected to present all antigens, mimicking natural infection. Codon deoptimization involves reducing the frequency of underrepresented codon pairs without changing amino acid sequences, resulting in a highly efficient virus attenuation strategy.

Vaccines 104

Vaccines Immunization Immunity Communication 104

Express Pharma

NOVEMBER 13, 2024

Bristol Myers Squibb and Cabaletta Bio are set to present promising Phase I data on CD19-directed CAR T therapies for severe, refractory lupus at the American College of Rheumatology 2024. Edits made by EP News Bureau The post CAR T cell therapies to promote drug-free remission in lupus care appeared first on Express Pharma.

Immunity 105

Immunity Immunization 105

pharmaphorum

APRIL 4, 2022

In particular, the findings suggest that disruption to innate immunity – the first line of defence against pathogens – as well as overly aggressive activity of white blood cells in the central nervous system called microglia. ” The post Study uncovers new Alzheimer’s genes, links to immune disruption appeared first on.

Immunity 52

Immunity Immunization 52

European Pharmaceutical Review

NOVEMBER 25, 2022

Certain RNA methyltransferases regulate RNA sensing and innate immune activation and represent novel immune-regulatory targets. We anticipate presenting results from our Phase I study in 2023.” In addition, STC-15 has shown efficacy in leukaemia models via mechanisms including inhibition of leukaemia stem cell function.

Immunity 98

Immunity Immunization 98

pharmaphorum

APRIL 8, 2022

Once within the tumour, it stimulates receptors on immune cells to mount an attack on the cancer. At the American Society of Haematology (ASH) meeting last December, the biotech presented data showing that the drug could halt the growth of tumours, with the effects lasting beyond the treatment phase.

Immunization 105

Immunization Immunity 105

European Pharmaceutical Review

MARCH 26, 2024

Moderna’s next-generation COVID-19 vaccine mRNA-1283 demonstrated a higher immune response against SARS-CoV-2, interim results from the company’s Phase III trial show. These findings were based on data comparing the treatment to mRNA-1273.222 (Spikevax ® ), Moderna’s licensed vaccine for the condition.

Vaccines 110

Vaccines Immunization Immunity 110

Pharmaceutical Business Review

MARCH 12, 2025

The research group at MD Anderson will carry out experiments to assess the preliminary efficacy and mechanistic data of the therapy, especially when combined with immune checkpoint inhibitors (ICIs) for treating HNSCC tumours. The company is set to retain the therapys title, interest, and complete rights.

Immunization 52

Immunization Immunity 52

Pharmacy Joe

SEPTEMBER 23, 2021

In this episode, I’ll discuss a possible syndrome that might herald vaccine-induced immune thrombotic thrombocytopenia. Episode 646: Does vaccine-induced immune thrombotic thrombocytopenia have a “pre-VITT syndrome” ? All 11 patients presented with severe headache 5 to 18 days after adenovirus vector vaccination.

Immunity 40

Immunity Immunization Vaccines Inpatient 40

pharmaphorum

NOVEMBER 29, 2022

Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy. T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents.

Immunity 105

Immunity Immunization Chemotherapy Compounding 105

pharmaphorum

JUNE 16, 2022

It also probably marks the end of the road for crenezumab, which Roche’s Genentech subsidiary licensed from AC Immune in 2006 in a deal initially valued at $300 million. Before the end of the year, Roche should report results from two phase 3 studies in early-stage patients.

Immunization 111

Immunization Immunity 111